(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy...
Stats | |
---|---|
今日成交量 | 316.00 |
平均成交量 | 5 830.00 |
市值 | 63.27M |
EPS | $0 ( 2024-04-24 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.11 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2008-10-06 | Driscoll Martin J | Buy | 4 999 | Options to acquire Common Stock |
2008-04-11 | Sanders Walter Lloyd | Buy | 65 000 | Restricted Stock Unit |
2007-01-03 | Sanders Walter Lloyd | Sell | 53 | Common Stock, par value $.001 |
2007-01-03 | Sanders Walter Lloyd | Sell | 51 | Common stock, par value $.001 |
2007-07-11 | Driscoll Martin J | Buy | 30 000 | Options to acquire Common Stock |
INSIDER POWER |
---|
0.00 |
Last 60 transactions |
Buy: 9 070 639 | Sell: 19 095 969 |
Genenta Science S.p.A. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-41 582.00 (0.00 %) |
EPS: | $-0.630 |
FY | 2023 |
营收: | $0 |
毛利润: | $-41 582.00 (0.00 %) |
EPS: | $-0.630 |
FY | 2022 |
营收: | $0 |
毛利润: | $-6 029.42 (0.00 %) |
EPS: | $-0.200 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.370 |
Financial Reports:
No articles found.
Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。